PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer

Area of Science:

• Biochemistry
• Molecular Biology
• Drug Discovery

Background:

• Cyclin-dependent kinases 4 and 6 (CDK4/6) are crucial regulators of the cell cycle.
• Dysregulation of CDK4/6 is implicated in various cancers, making them attractive therapeutic targets.
• Existing therapies often focus on inhibiting CDK4/6 activity.

Purpose of the Study:

• To develop novel Proteolysis-Targeting Chimeras (PROTACs) for the degradation of CDK4/6 proteins.
• To evaluate the efficacy of these PROTACs in inducing target degradation and downstream cellular effects.
• To establish the potential of PROTAC technology for targeting CDK4/6.

Main Methods:

• Design and synthesis of PROTACs utilizing FDA-approved CDK4/6 inhibitors.
• Assessment of PROTAC-mediated degradation of CDK4/6 proteins.
• Evaluation of retinoblastoma protein (Rb) phosphorylation suppression.
• Analysis of cell cycle arrest induction.
• Determination of compound activity at nanomolar concentrations.

Main Results:

• PROTACs were successfully generated using selective, FDA-approved CDK4/6 inhibitors.
• One palbociclib-based PROTAC demonstrated potent degradation of CDK4/6 proteins.
• This PROTAC effectively suppressed Rb phosphorylation, leading to cell cycle arrest.
• The developed PROTACs exhibited activity at nanomolar concentrations.

Conclusions:

• PROTACs represent a novel and effective strategy for targeting CDK4/6 proteins.
• Palbociclib-based PROTACs show significant promise for cancer therapy by inducing targeted protein degradation.
• These findings highlight the potential of PROTACs as a new class of therapeutics for CDK4/6-driven malignancies.